Welcome to our dedicated page for Sharps Tech news (Ticker: STSS), a resource for investors and traders seeking the latest updates and insights on Sharps Tech stock.
Sharps Technology Inc. (STSS) delivers innovative safety syringe solutions for global healthcare markets. This page provides official updates on corporate developments, product advancements, and strategic initiatives shaping the medical device sector.
Access timely announcements including earnings reports, manufacturing expansions, and partnership agreements. Investors and healthcare professionals will find critical updates on STSS's ultra-low waste syringes, smart-safety features, and regulatory compliance milestones.
Our curated news collection supports informed analysis of STSS's market position, emphasizing its patented technologies and quality assurance protocols. Bookmark this page for reliable updates on contract wins, production scaling, and industry trends impacting drug delivery systems.
Sharps Technology (NASDAQ: STSS) CEO Robert Hayes addresses shareholders about the impact of recent FDA actions and tariffs. The FDA raised quality concerns over Chinese syringes in November 2023, leading to recalls and warnings in early 2024. The Biden Administration increased tariffs on Chinese syringes from 0% to 50% in May 2024. Sharps Technology, with its high-quality syringe products like SecureGard and SoloGard, is poised to fill the supply gap. The company manufactures in Hungary and plans to add a US facility. Sharps has also formed partnerships with Roncadelle Operations and Owens & Minor to expand market reach and distribution. These steps are expected to drive revenue growth and market presence.
FAQ
What is the current stock price of Sharps Tech (STSS)?
What is the market cap of Sharps Tech (STSS)?
